All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

Nektar Therapeutics Q3 2026 net loss widens 57% to $55.65 million

By Public Technologies
  • Nektar Therapeutics' third-quarter 2026 net loss widened 57% to $55.65 million, while revenue fell 20% to $9.39 million.
  • Research and development expenses rose 62% to $44.12 million, primarily due to Phase 3 program support and rezpegaldesleukin manufacturing activities.
  • Cash and marketable securities investments more than tripled to $952.9 million at September 30 from December 31, 2025.
  • All three Phase 3 ZENITH AD trials have started, with the ZENITH AA trial scheduled to begin in December 2026.
  • Initial ZENITH AD topline data are expected in mid-2028, with a BLA submission targeted for 2029.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nektar Therapeutics published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611121615PR_NEWS_USPR_____SF94209) on November 12, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.